Drugs / LP-118
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07614022 | Oct 2026 → Mar 2030 expected | precursor B-cell acute lymphoblastic leukemia | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04771572 | May 2022 → Dec 2026 expected | Richter transformation, T-cell prolymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +4 | Newave Pharmaceutical Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT05025358 | Sep 2021 → Jul 2025 | cancer, non-Hodgkin lymphoma | Guangzhou Lupeng Pharmaceutical Company LTD. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06207123 | Sep 2024 → Dec 2026 expected | acute leukemia, lymphoblastic lymphoma | University of Chicago | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP-118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07614022 ↗ |
| Action | Inhibit | “LP-118 is a BCL-2/BCL-XL small molecule inhibitor.” NCT05025358 ↗ |
| Modality | Small molecule | “LP-118 is a BCL-2/BCL-XL small molecule inhibitor.” NCT05025358 ↗ |
| Route | Oral | “LP-118 under a once daily oral dosing schedule” NCT04771572 ↗ |